Abstract
In the article published in the current issue of European Heart Journal, Schomig and collaborators identify new humoral factor associated with the release of progenitor cells in acute myocardial infarction (AMI). The article expands current knowledge with regard to mobilization of bone-marrow progenitors in AMI by showing that parallel to already described increase of vascular endothelial growth factor, there is a marked upregulation of interleukin-8 (IL-8) in patients with AMI treated with primary percutaneous coronary intervention (PCI). The increase of IL-8 levels shows the similar time-course as the mobilization of CD133+ cells, moreover plasma concentrations of IL-8 and were shown to be an independent predictor of circulating CD133+ cells number in multivariable regression model that included parameters known to influence the progenitor cell mobilization, such as cardiovascular risk factors, infarct size, and use of statins. Authors investigated the mobilization of three populations of circulating cells differentiated according to their immunophenotype and in vitro characteristics: endothelial progenitor cells (EPC), mature endothelial cells (EC), and less well-defined CD133+ CD34+ CD45− progenitor cells.1 EPC are capable of transforming into mature, functional EC and can be regarded as the pool of cells maintaining the integrity of vascular endothelium, as numerous studies confirmed their pivotal role in vasculogenesis and angiogenesis after ischaemic injury in the setting of AMI and peripheral artery disease.2 Shintani et al .3 were the first to describe and characterize the CD34+ mononuclear cells positive for lineage markers (KDR, VE-cadherin, CD31) as well as function (Dil-acLDL uptake) and morphology of EPC which were mobilized into peripheral blood in AMI. These findings were subsequently confirmed and expanded by Masa et al .,4 in AMI patients … *Corresponding author. Tel: +48 604188669; fax: +48 32 2523930. E-mail address : wojwoj{at}mp.pl
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
